Form 8-K - Current report:
SEC Accession No. 0001279569-22-000371
Filing Date
2022-03-10
Accepted
2022-03-10 10:52:55
Documents
13
Period of Report
2022-03-09
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K essa8k.htm   iXBRL 8-K 45483
2 OMNIBUS INCENTIVE PLAN ex991.htm EX-99.1 107155
  Complete submission text file 0001279569-22-000371.txt   355704

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA epi-20220309.xsd EX-101.SCH 3063
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE epi-20220309_lab.xml EX-101.LAB 34476
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE epi-20220309_pre.xml EX-101.PRE 22616
7 EXTRACTED XBRL INSTANCE DOCUMENT essa8k_htm.xml XML 3691
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37410 | Film No.: 22727899
SIC: 2834 Pharmaceutical Preparations